KR20190086591A - 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 - Google Patents

암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 Download PDF

Info

Publication number
KR20190086591A
KR20190086591A KR1020197020313A KR20197020313A KR20190086591A KR 20190086591 A KR20190086591 A KR 20190086591A KR 1020197020313 A KR1020197020313 A KR 1020197020313A KR 20197020313 A KR20197020313 A KR 20197020313A KR 20190086591 A KR20190086591 A KR 20190086591A
Authority
KR
South Korea
Prior art keywords
pyridin
methyl
pyrrolo
yloxy
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197020313A
Other languages
English (en)
Korean (ko)
Inventor
밀란 브룬코
훙 딩
조지 도허티
스티븐 엘모어
리사 하스볼드
로라 헥사머
아론 알. 쿤저
샤오훙 쑹
앤드류 제이. 사우어스
제라드 설리반
즈-푸 타오
게리 티. 왕
러 왕
시루 왕
마이클 웬트
로버트 맨타이
토드 엠. 한센
Original Assignee
애브비 아일랜드 언리미티드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42677657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190086591(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애브비 아일랜드 언리미티드 컴퍼니 filed Critical 애브비 아일랜드 언리미티드 컴퍼니
Publication of KR20190086591A publication Critical patent/KR20190086591A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197020313A 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 Abandoned KR20190086591A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18120309P 2009-05-26 2009-05-26
US61/181,203 2009-05-26
PCT/US2010/036198 WO2010138588A2 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032920A Division KR102001418B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033737A Division KR20190130676A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제

Publications (1)

Publication Number Publication Date
KR20190086591A true KR20190086591A (ko) 2019-07-22

Family

ID=42677657

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020197020313A Abandoned KR20190086591A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020187032920A Active KR102001418B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020197033737A Pending KR20190130676A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020117030916A Active KR101659583B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020237028352A Pending KR20230128571A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020177008201A Abandoned KR20170037683A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020187011857A Active KR101920202B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020157014221A Active KR101723378B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020187032920A Active KR102001418B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020197033737A Pending KR20190130676A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020117030916A Active KR101659583B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020237028352A Pending KR20230128571A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020177008201A Abandoned KR20170037683A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020187011857A Active KR101920202B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020157014221A Active KR101723378B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제

Country Status (43)

Country Link
US (1) US8580794B2 (https=)
EP (5) EP4474383A3 (https=)
JP (9) JP5747025B2 (https=)
KR (8) KR20190086591A (https=)
CN (5) CN104906100A (https=)
AR (2) AR076705A1 (https=)
AU (1) AU2010254160C1 (https=)
BR (2) BR122019016429B1 (https=)
CA (4) CA2929347A1 (https=)
CL (1) CL2011002949A1 (https=)
CO (1) CO6480950A2 (https=)
CR (2) CR20170019A (https=)
CY (2) CY1117423T1 (https=)
DK (1) DK2435432T6 (https=)
DO (1) DOP2011000367A (https=)
EC (1) ECSP11011554A (https=)
ES (1) ES2546294T7 (https=)
FI (1) FI2435432T6 (https=)
HK (1) HK1215576A1 (https=)
HR (1) HRP20151001T4 (https=)
HU (2) HUE027698T2 (https=)
IL (6) IL319747A (https=)
LT (1) LTC2435432I2 (https=)
ME (1) ME02205B (https=)
MX (2) MX339469B (https=)
MY (1) MY155645A (https=)
NL (1) NL300873I2 (https=)
NO (1) NO2017023I1 (https=)
NZ (1) NZ595708A (https=)
PE (1) PE20120345A1 (https=)
PH (1) PH12015500297B1 (https=)
PL (1) PL2435432T6 (https=)
PT (1) PT2435432E (https=)
RS (1) RS54234B2 (https=)
RU (3) RU2573832C2 (https=)
SG (2) SG175253A1 (https=)
SI (1) SI2435432T2 (https=)
SM (1) SMT201500225B (https=)
TW (3) TWI537269B (https=)
UA (1) UA106079C2 (https=)
UY (3) UY32668A (https=)
WO (1) WO2010138588A2 (https=)
ZA (1) ZA201108616B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2376480T3 (en) * 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2747835A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
US9108910B2 (en) 2011-02-15 2015-08-18 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
CA2879332C (en) * 2012-08-13 2022-08-30 Abbvie Inc. 1,2,3,4- tetrahydroisoquinoline-8-carboxamide compounds and their use as apoptosis-inducing agents
HK1212240A1 (en) 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
AU2013337717B2 (en) * 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
TR201908138T4 (tr) 2015-07-07 2019-06-21 Hoffmann La Roche Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
EP3426655A1 (en) 2016-03-10 2019-01-16 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
CA3017408C (en) 2016-03-15 2025-08-19 Oryzon Genomics, S.A. LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
US10829488B2 (en) * 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
EP3565815B1 (en) * 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
TWI773730B (zh) 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
EP3612531B1 (en) * 2017-04-18 2022-08-24 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN110759908B (zh) 2017-06-26 2021-03-12 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
JP2020528418A (ja) 2017-07-26 2020-09-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CN111511748B (zh) 2017-08-23 2023-05-02 广州麓鹏制药有限公司 Bcl-2抑制剂
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CN112135631A (zh) 2018-02-16 2020-12-25 艾伯维公司 用于癌症治疗的选择性bcl-2抑制剂与抗pd-1或抗pd-l1抗体的组合
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
SG11202009933WA (en) * 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
TW202023568A (zh) 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
BR112020018978A2 (pt) 2018-07-31 2021-03-02 Ascentage Pharma (Suzhou) Co., Ltd. produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
AU2019372640B2 (en) 2018-10-29 2022-08-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor
CN109320516A (zh) * 2018-11-30 2019-02-12 重庆三圣实业股份有限公司 一种维奈妥拉中间体的制备方法及其产品
CN109438441A (zh) * 2018-11-30 2019-03-08 重庆三圣实业股份有限公司 一种维奈妥拉的制备方法及其产品
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
US12319689B2 (en) 2019-05-24 2025-06-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN112661751B (zh) * 2019-10-16 2024-06-14 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
US12552784B2 (en) 2019-12-27 2026-02-17 Newave Pharmaceutical Inc. 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
US12545674B2 (en) 2020-04-29 2026-02-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
CN114478520B (zh) * 2020-10-28 2025-01-10 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
MX2023011000A (es) 2021-03-19 2023-09-28 Eil Therapeutics Inc Compuestos que contienen ((3-nitrofenilo)sulfonilo)acetamida como inhibidores bcl-2.
WO2022218311A1 (en) * 2021-04-13 2022-10-20 Appicine Therapeutics (Hk) Limited Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
US20240287110A1 (en) 2021-06-04 2024-08-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phosphate of trifluoromethyl-substituted sulfonamide compound
EP4396180A4 (en) * 2021-08-31 2025-07-09 Beigene Ltd SOLID FORMS OF BCL-2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
CA3241668A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
JP2025525609A (ja) * 2022-07-21 2025-08-05 ベイジーン スイッツァランド ゲーエムベーハー Ｂｃｌ－２阻害剤を使用する多発性骨髄腫の治療方法
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
NZ257955A (en) * 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
EP1019399A1 (en) * 1997-10-03 2000-07-19 Merck Frosst Canada & Co. Aryl thiophene derivatives as pde iv inhibitors
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6787534B2 (en) * 1999-12-28 2004-09-07 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7183320B2 (en) 2001-06-06 2007-02-27 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
US20030059489A1 (en) 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US6995787B2 (en) 2002-08-21 2006-02-07 Adams Steven L Sports projectile and camera apparatus
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
MXPA06014754A (es) * 2004-06-17 2007-06-22 Infinity Pharmaceuticals Inc Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
PL1888550T3 (pl) * 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
RU2387653C2 (ru) 2005-05-16 2010-04-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070115787A1 (en) * 2005-11-23 2007-05-24 Seagate Technology Llc Planar optical device for generating optical nanojets
JP5277168B2 (ja) * 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
AU2008242703B2 (en) 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) * 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2376480T3 (en) 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
CA2747835A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083442A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법

Also Published As

Publication number Publication date
CN104876927B (zh) 2017-06-23
BRPI1014359B1 (pt) 2019-11-05
KR20170037683A (ko) 2017-04-04
NO2017023I2 (no) 2017-05-29
AR109974A2 (es) 2019-02-13
IL215644A0 (en) 2012-01-31
KR101723378B1 (ko) 2017-04-06
CN104876927A (zh) 2015-09-02
RU2015154494A (ru) 2017-06-22
KR20150065947A (ko) 2015-06-15
CA2759182A1 (en) 2010-12-02
MX2011012257A (es) 2011-12-16
MY155645A (en) 2015-11-13
UY33047A (es) 2011-09-30
SG175253A1 (en) 2011-11-28
LTC2435432I2 (lt) 2018-06-11
JP2025072583A (ja) 2025-05-09
EP2435432B3 (en) 2023-10-25
KR20180124164A (ko) 2018-11-20
UY37825A (es) 2020-02-28
IL286036A (en) 2021-10-31
ZA201108616B (en) 2015-12-23
WO2010138588A9 (en) 2011-05-05
EP2435432B1 (en) 2015-06-24
KR20120034671A (ko) 2012-04-12
KR101920202B1 (ko) 2018-11-21
JP2015110605A (ja) 2015-06-18
CA2759182C (en) 2016-06-07
EP2435432A2 (en) 2012-04-04
CN109897038B (zh) 2022-04-05
EP4474383A3 (en) 2025-02-19
AR076705A1 (es) 2011-06-29
TWI476195B (zh) 2015-03-11
HUS1700021I1 (hu) 2017-06-28
UA106079C2 (uk) 2014-07-25
CR20110632A (es) 2012-02-15
RU2535347C3 (ru) 2019-05-14
TW201107323A (en) 2011-03-01
DOP2011000367A (es) 2017-07-31
IL299019A (en) 2023-02-01
JP5747025B2 (ja) 2015-07-08
HK1215576A1 (en) 2016-09-02
ES2546294T7 (es) 2024-06-06
AU2010254160C1 (en) 2023-07-06
US8580794B2 (en) 2013-11-12
SI2435432T1 (sl) 2015-10-30
TW201506025A (zh) 2015-02-16
JP2012528178A (ja) 2012-11-12
LTPA2017015I1 (lt) 2017-06-12
TWI537269B (zh) 2016-06-11
KR102001418B1 (ko) 2019-07-19
WO2010138588A2 (en) 2010-12-02
ME02205B (me) 2016-02-20
RU2573832C2 (ru) 2016-01-27
HK1163099A1 (en) 2012-09-07
EP4682148A3 (en) 2026-03-18
AU2010254160A1 (en) 2011-11-24
CY2017019I2 (el) 2018-01-10
ECSP11011554A (es) 2012-01-31
PH12015500297B1 (en) 2023-10-20
PH12015500297A1 (en) 2015-12-07
MX2019012154A (es) 2019-11-21
PL2435432T3 (pl) 2015-12-31
TW201607946A (zh) 2016-03-01
RU2628885C2 (ru) 2017-08-22
KR20230128571A (ko) 2023-09-05
IL215644A (en) 2017-08-31
JP6353506B2 (ja) 2018-07-04
CA3206963A1 (en) 2010-12-02
CN102448959B (zh) 2015-06-17
JP2017048219A (ja) 2017-03-09
CO6480950A2 (es) 2012-07-16
NL300873I2 (nl) 2017-10-24
MX339469B (es) 2016-05-27
RU2011152973A (ru) 2013-07-10
JP2018138577A (ja) 2018-09-06
HRP20151001T4 (hr) 2024-02-16
KR101659583B1 (ko) 2016-09-29
CY1117423T1 (el) 2017-04-26
EP3656771A1 (en) 2020-05-27
JP6038195B2 (ja) 2016-12-07
JP2020023545A (ja) 2020-02-13
FI2435432T6 (fi) 2023-11-21
EP4682148A2 (en) 2026-01-21
CN104906100A (zh) 2015-09-16
EP2944638A1 (en) 2015-11-18
WO2010138588A3 (en) 2011-04-07
EP4474383A2 (en) 2024-12-11
IL319747A (en) 2025-05-01
HUE027698T2 (en) 2016-10-28
SMT201500225B (it) 2015-10-30
HRP20151001T1 (hr) 2015-10-23
CN109966294A (zh) 2019-07-05
US20110124628A1 (en) 2011-05-26
CA3052016A1 (en) 2010-12-02
IL253891A0 (en) 2017-10-31
RU2014132884A (ru) 2015-12-27
SG10201704742YA (en) 2017-07-28
SI2435432T2 (sl) 2024-04-30
RS54234B2 (sr) 2024-02-29
NO2017023I1 (no) 2017-05-29
NZ595708A (en) 2014-03-28
PL2435432T6 (pl) 2024-02-12
PT2435432E (pt) 2015-10-13
BR122019016429B1 (pt) 2020-03-24
PE20120345A1 (es) 2012-05-17
CA2929347A1 (en) 2010-12-02
AU2010254160B2 (en) 2015-02-12
CY2017019I1 (el) 2018-01-10
CR20170019A (es) 2017-05-12
BRPI1014359A2 (pt) 2016-04-05
DK2435432T6 (da) 2023-12-18
DK2435432T3 (en) 2015-08-31
JP2026001072A (ja) 2026-01-06
JP2022033939A (ja) 2022-03-02
ES2546294T3 (es) 2015-09-22
IL269092A (en) 2019-11-28
CN102448959A (zh) 2012-05-09
RS54234B1 (sr) 2015-12-31
RU2535347C2 (ru) 2014-12-10
KR20190130676A (ko) 2019-11-22
TWI561523B (en) 2016-12-11
CN109897038A (zh) 2019-06-18
CL2011002949A1 (es) 2012-05-25
KR20180049164A (ko) 2018-05-10
UY32668A (es) 2010-12-31
JP2023040165A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
KR102001418B1 (ko) 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US9045475B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US11897864B2 (en) Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2015202183B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190711

Application number text: 1020187032920

Filing date: 20181113

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190807

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190813

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191114

Application number text: 1020187032920

Filing date: 20181113

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee